Trial · NCT01087723
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding | Bivalirudin | 5.1 | percentage of participants | ||
| The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding | Standard of Care: Heparins With Optional GPI | 8.5 | percentage of participants | ||
| The Composite Incidence of Death, Re-infarction (MI), or Non-CABG Major Bleeding | Bivalirudin | 6.6 | percentage of participants | ||
| The Composite Incidence of Death, Re-infarction (MI), or Non-CABG Major Bleeding | Standard of Care: Heparins With Optional GPI | 9.2 | percentage of participants | ||
| The Incidence of Death, Re-infarction, Non-CABG-related Major Bleeding, or Ischemia-driven Revascularization (IDR) | Bivalirudin | Death | 2.9 | percentage of participants | |
| The Incidence of Death, Re-infarction, Non-CABG-related Major Bleeding, or Ischemia-driven Revascularization (IDR) | Standard of Care: Heparins With Optional GPI | Death | 3.1 | percentage of participants | |
| The Incidence of Death, Re-infarction, Non-CABG-related Major Bleeding, or Ischemia-driven Revascularization (IDR) | Bivalirudin | Re-infarction | 1.7 | percentage of participants | |
| The Incidence of Death, Re-infarction, Non-CABG-related Major Bleeding, or Ischemia-driven Revascularization (IDR) | Standard of Care: Heparins With Optional GPI | Re-infarction | 0.9 | percentage of participants | |
| The Incidence of Death, Re-infarction, Non-CABG-related Major Bleeding, or Ischemia-driven Revascularization (IDR) | Bivalirudin | Non-CABG-related major bleeding | 2.6 | percentage of participants | |
| The Incidence of Death, Re-infarction, Non-CABG-related Major Bleeding, or Ischemia-driven Revascularization (IDR) | Standard of Care: Heparins With Optional GPI | Non-CABG-related major bleeding | 6.0 | percentage of participants | |
| The Incidence of Death, Re-infarction, Non-CABG-related Major Bleeding, or Ischemia-driven Revascularization (IDR) | Bivalirudin | IDR | 2.2 | percentage of participants | |
| The Incidence of Death, Re-infarction, Non-CABG-related Major Bleeding, or Ischemia-driven Revascularization (IDR) | Standard of Care: Heparins With Optional GPI | IDR | 1.5 | percentage of participants | |
| The Incidence of Death at 1 Year | Bivalirudin | 5.4 | percentage of participants | ||
| The Incidence of Death at 1 Year | Standard of Care: Heparins With Optional GPI | 5.3 | percentage of participants | ||
| The Incidence of Major Bleeding: Thrombolysis in MI (TIMI) and Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries (GUSTO) | Bivalirudin | Major bleeding: TIMI | 1.3 | percentage of participants | |
| The Incidence of Major Bleeding: Thrombolysis in MI (TIMI) and Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries (GUSTO) | Standard of Care: Heparins With Optional GPI | Major bleeding: TIMI | 2.1 | percentage of participants | |
| The Incidence of Major Bleeding: Thrombolysis in MI (TIMI) and Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries (GUSTO) | Bivalirudin | Major bleeding: GUSTO | 1.3 | percentage of participants | |
| The Incidence of Major Bleeding: Thrombolysis in MI (TIMI) and Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries (GUSTO) | Standard of Care: Heparins With Optional GPI | Major bleeding: GUSTO | 2.3 | percentage of participants | |
| The Incidence of Minor Bleeding: TIMI and GUSTO | Bivalirudin | Minor bleeding: TIMI | 6.5 | percentage of participants | |
| The Incidence of Minor Bleeding: TIMI and GUSTO | Standard of Care: Heparins With Optional GPI | Minor bleeding: TIMI | 11.2 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01087723/results